GTHX - Earnings call 2 2022 | G1 Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the G1 Therapeutics Second Quarter 2020 Financial Results Call. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker for today, Mr. William Roberts. ahead. go Please

William Roberts

financial of Good 'XX, of conference on period Mike. our COSELA, the incidence a financial A prepared cell follow quarter and small to commercially containing update a morning's in in team on including welcome and progress which and commercial or etoposide the this Thank be call, corporate question-and-answer can to morning, cancer to decrease session lung overview website, will prior discuss business myelosuppression to platinum and second GX topotecan found these release press call and regimen an update. adult news 'XX provide containing was our programs the for of issued clinical business morning our section administered remarks. you, the the or ES-SCLC. The everyone, patients approved in results extensive-stage the our with second that will results chemotherapy-induced this quarter available when of is regimen gXtherapeutics.com. On

today represent risks contains to judgment I by cause differ Act begin, webcast expressed that or of statements. today's those Litigation meaning in statements Such results Private within remind implied and these the XXXX. uncertainties statements you that we want of of Reform involve to as the Before and actual forward-looking may Securities management's could materially from

today, filings XXXX. with Any the views and For more August of Securities SEC our website. our information on uncertainties, the on represent forward-looking corporate to such risks Commission, X, our refer available or which and as Exchange statements are from please

call Chief Chief Financial to our Commercial the Jack. and Moses, Medical call Officer; that, the today Raj over Chief our Executive Andrew Officer; Perry, our on Chief with turn our Joining Officer; Jen I'll Malik, Officer. And are Jack me Bailey,

John Bailey

them. for headline ourselves milestones call. Will, we on set morning, first half of important that is for variety briefly of foundational for touch good Today's everyone. joining a Thanks, the X we XXXX. and I'll achieved of that Thanks us the have on

the decisiveness the regarding First, execution commercialization prescribers identified over issue top of access by target building made correct an inflection strategic own few better quarters We of sales the the executed team. COSELA We and COSELA. saw as sales. to decisively during we accounts. I'm to the decisions course, right of the shown the quickly our and And proud needing a result, including quarter, team in and GX focused past

cell to momentum multiple quarter team covers as with patients in small important reactively hematologic we than proactively enabling interventions, serious is ever and than first to before. lineage is unintended COSELA more potentially the evident a is lung them our reduce innovative dangerous this and time consequences. preemptively and of worked drug. experienced to administered which, cancer drug oncologists for The bring It with side unique lineages, for or the single treating the effects of rather waiting carry of variety course, chemotherapy prevent own their an

including the we vial period-over-period. by volume hear XX% from experienced good you'll Andrew, almost quarter, during As growth growing

cancer. enrollment we in of XXX the the quarter milestone importantly, participants of of COVID-XX majority trials well line period headwinds, programs ongoing second achieved significant in the of and extension Most our important during has with Second, including clinical of the Ukraine, trilaciclib clinical products. in executed different team many impacted Phase in completing crisis trial extremely our which colorectal III the a metastatic

trial II morning's our read bladder in for primary mechanism We And II this [Audio as Phase those expect our the press of assessing the from recently the trilaciclib. initial in in of results, also Gap], had you both enrollment we release, quarter first key including the action milestones XXXX. endpoint Phase

Phase ongoing results the initial Raj, this you starting the hear year. our will III quarter months II fourth trials and clinical we from in Phase expect to the as provide each of from coming X Further, over of XX

were recently authorization conditionally with perspective, for China use was to jointly Greater had COSELA corporate which share Simcere. that marketing Products a from very developed Third, the pleased we for Medical the China in in approved National partnership Administration

a a million part total result, milestone Simcere, to consideration of payment As from GX a receive will milestone million. up of $XX $XXX

net call. on expect double-digit also in royalties in the describe receive China, which COSELA We to later annual future sales will Jen of

including our I team during of morning, Andrew momentum, our our including efforts lines of new to an will second will This then progress, on our provide the quarter and cover field recent first snapshot sales a XXXX. clinical time Raj ask commercial update expectations. of data

financial the an call a of for into quarter, runway and Andrew. Then over cash I'll back the provide be reminder concluding our the turn that sincere on will Jen ramifications approval some comments. With us the for update to including Finally, that, takes results financial I'll XXXX.

Andrew Perry

of Thank you, and sales performance update of growth. today leading Jack. second I'm including a with on number commercial an topics, to glad be to you quarter indicators provide

The Oncology managers and of was deployment account second own in the of with termination or first our during Boehringer COSELA March. GX sales by team our following early quarter OSAM complete period our mid-February Ingelheim solely in was co-promotion which full agreement promoted their

demonstrate cell XXX extensive-stage to goal XX% of top small Our cancer. second on who lung the volume in around focus organizations quarter growth significant the a see with patients was with

for wanted also utilization growth build demonstrating breads of both depth a platform to U.S. the future We by across and

in volume second of to launch, month-over-month quarter was and ended we launch vial sales the XX% in volumes. tripled of Beginning $X.X the after saw This growth representing COSELA, year month last XXXX, which has full highest rate and million first activity. vial growth with in positive Each this quarter in rates was compared quarter QX almost nearly growth our the in in the We showed growth growth of XXX%. net quarter-over-quarter. same our quarterly the volume initial with in period the QX year quarter was sales since

month-to-month care pattern organizations of can health did and reflect times on cell different to prior not last saw year. However, and months. similar in rate of we And cancer July growth at lung our due from in the pressure small patient the the staffing show year, flow variability market to

However, stronger a execution and the number initiate we marketing designed growth, improve our growth. and restore initiatives and anticipate continued of sales we've taken do further opportunity quarter-over-quarter to to

We And with XX% covered covered government of commercial by our Medicaid quarter saw volume in volume in mix in XX% of the in program. our broadly programs. remained and the through our the Medicare, come and XX% unchanged patient or and XX% X% by quarter remainder hospitals coming pair with centers. through assistance clinics volume commercial was from supply XX% academic community come of

ranging to our driving rates deliver only platform with but base all I'm growth, quarter, to in earlier, mentioned goal was by utilization I and of during for regions also growth not to the our our regional sales our key XX% pleased of depth report As future to accounts. quarterly broadening higher a X growth contributed XX%. growth in the that U.S. national from to deliver

XX territories quarter. in demonstrated fact, our XXX% over growth XX the of In of

total the cancer, also with in second in portfolio XX% expand XX% which end uptick of We was X have organizations, our in had our a top organizations giving since wanted top treat quarter. cell to was XXX QX small XXX added of proportion our business reach XXX patients which we QX, of have us and XXX organizations those XX lung XX%, those top top the extensive-stage of Approximately trialed during and the around The repeat and top XX%. COSELA. of organizations XXX the growth of orders important

of awareness for remains above COSELA matters brand XX% and some execution, of of overall within messages intending COSELA XX% at within over over brand with high effectiveness are prescribe prescribe COSELA commercial majority aware of industry is XX intending to who averages. to the Message to months. Moving XX%, around or oncology at X months physicians

date. such reimbursement to Third-party payer medical conferences strong, face-to-face major were the in few We've and for remained very our ONS and payer had we excited now also with an GX at have opportunities and calls have commercial COSELA engagement with representing and increase Therapeutics we as AFFO majority of this teams in person, to seen has quarter. our customers, and rejections

significantly key business base Overall, pleased support QX. can continue to stronger our and in a we're the which forward. We of delivered organizations, broader going growth with customer across growth progress built

more lead key all COSELA for of measures success even In show potential the Our future.

benefit As necessary in their ensuring patients a to result, clinical extensive-stage to that, a COSELA cell for small first. regimens. With their update resources many include to and we the COSELA cancer, lung for medical to potential the over more of the call I'll providers remain Raj ambitious have information and committed with we're health and turn care

Rajesh Malik

everyone. Andrew, Thanks, good morning, and

time the initial the mentioned, we lines Jack our disclosed. expect X previously ongoing I today, have can As trials that as clinical in provide report results from we of to

objective, XXXX. data that efficacy As final primary this where to the published of cancer is fourth it assessment and about we important Phase and data the context the is of quarter for reported understand studies, think breast will Onset the that II in initial in antitumor triple-negative the be Oncology XXXX as in were year through

may of ratios receiving control II data, in in the the improvements As trilaciclib observed from hazard X.X overall we X.XX in recall you TNBC survival the meaningful robust X Phase group trilaciclib clinically in to patients patients endpoint compared most and the of statistically significant with groups.

and And the but strong, in was between least progression-free response control overall on trilaciclib not was difference as survival the effect arms The robust survival. rate. as

expecting with hypothesis inhibitors. that as Our the response checkpoint compared and improve response from mechanism greater effect consistent EFS so trilaciclib rate immune data survival action to therapies a could more the is see This system that is than immuno-modulating modulate to are rate. immune of on such OAS of

could durability of Phase of occur a for T greater memory expect Specifically, antitumor studies formation we that focused improve to II on CDX+ Therefore, increased may see long-term effect the trilaciclib survival the on effect assessing our cells, then response our of our immune through of efficacy, which our on trials Phase believe for expected we coming rate. I and III least progression-free you or line time over II on months, remind Phase Pivotal and with data moving starting program. to the XX overall surveillance.

completed we exposure in in effective important potentially most of the and recently metastatic FOLFOXIRI milestone as first-line called efficacy. we foremost, X. colorectal result also improve PRESERVE is antitumor patient myelotoxic greater myelotoxicity the also for in most a enrollment our Improving and and chemotherapy colorectal to metastatic trilaciclib trial regimen cancer. achieved First XXX could an cancer

release expect of initial primary of first endpoint quarter including the trial, from this rate the in from response myeloprotection secondary overall results and We those the endpoint XXXX. to from of

The endpoints the later. in meet data come PFS of with we this If for will filing authorities to regulatory will are myeloprotection approval secondary discuss and OS survival positive, indication.

conducted by positive in first-line Second, XXX trial to not, with analysis If expect trial it pivotal we second half trial data stopping year. the patients we regarding survival be approximately of committee our the analysis PRESERVE tumors, our If overall meets it will TNBC X, report negative PD-LX monitoring to next the the the interim line the will in the continue does interim rule, and terminate, will analysis. and final results. top

We initial checkpoint regarding the fourth expect trials. treatment. bladder data quarter with this immune in Next, trilaciclib year. currently in cancer receiving chemotherapy X Starting our the avelumab PRESERVE of Phase first-line from study of the our inhibitor X, of patients II following with and with

days. in, Jack enrollment last that so enroll approximately In we to patients morning shortly, X achieved so XX upcoming should The trial. consented As we patient do this this our have we the in announced mentioned, who should achieve have patient last target

As such, on fourth response of data quarter XXXX. we PFS provide in confirm followed this of rate expect the primary year, line initial that mono in data can and the endpoint protection we to by top

action trial of Second, in to clarify XX-patient neoadjuvant the we've breast in mechanism also participants of completed triple-negative with enrollment cancer. our trilaciclib

in endpoint We or including microenvironment of on data cells and results cells in provide tumor and T year expect in this this trilaciclib's the complete regs regulatory initial to pathological the other XXXX. immune CDX+ with from T fourth response impact quarter trial, profiling T immune

which of II continued U.S. preliminary the trilaciclib to with news safety usage disease, in designed Phase drug breast the our resulting neoadjuvant expect landscape from trial antibody combination change triple-negative great in pembrolizumab sacituzumab govitecan. the cancer in potential is evaluate setting, conjugate, additive to greater present has of patients. we to of slower in data the and for treatment Third, adjuvant The with progression

factors that eligible As has the to one out, to become pushed slower which patient for could until a be our the contributed a result, appears trial of time has enrollment.

of the sites. mitigating We are variety in this of adding in ways, a process additional including

next the many possible As is worth bulk year. It's effect of and including landscape preliminary year a evolution a safety late as the result, data, only. we'll U.S. data efficacy this from this noting have as patients that

these TNBC global seeing in hurdles not Pivotal enrollment trial. the are We

Finally, with expediting lung evaluation a of chemotherapy cancer. of significant and checkpoint the there combination strategic the cell inhibitor first-line to are non-small importance in trilaciclib

we're than As as with of supporting means partner. rather a such, sponsoring an it such evaluation ourselves exploring investigator-initiated study, or other

possible call We the review will I'll ongoing a the financial as our over as to soon provide initiate. and abreast With this an also those results of keep as turn of the update on of trials that, for ISS you for Jen second XXXX. quarter program

Jennifer Moses

Raj, good morning, Thanks, everyone. and

Will mentioned, results morning's intend be XXXX press market after of will As and to in second file for this XX-Q, today the all the which close. available financial quarter release in are we

of same revenue of million of $XX.X period XXXX, million total net Our million, June million for million total the comprised $X revenue compared $X.X of $X.X to sold revenue license to period million of compared Cost XXXX. XXXX goods X revenue of months for $X.X and $X.X COSELA the the same second was XXXX. was ended for the for in XX, in quarter

therefore, of As recorded a nominal portion prelaunch majority a prior and as goods were inventory a in of R&D been cost the approval to going of treatment periods. and to forward. now were on sold costs depleted, of COSELA has costs these incurred The will sales the impact related manufacturing prior have FDA expense reminder,

increase manufacturing in were Our the trials. clinical quarter spend, due a $XX.X pharmaceutical drug of The primarily for and and to for cost research million offset R&D active in expenses ingredients the quarter to expense trial for of an decrease second in compared of for XXXX. development was by XXXX increase second product million $XX.X clinical

mentioned fourth line in in third in and the come saw of we the XXXX we as of the with this As more on quarter last spend level R&D annual and XXXX to with first outlier, expect above the we XXXX call, second quarter quarter what the year.

for were quarter-over-quarter compared second was expenses fees administrative medical expenses headcount, to the Our increase the due second in million XXXX decrease by and to selling, quarter commercialization increase The of personnel related for activities, affairs costs. IT-related legal XXXX. SG&A of general and $XX.X offset $XX.X largely in million professional quarter cost, a an to costs in and

We continue expenses our disciplined monitor in manner. a to

data monitor allows we are time us are investing to lines spend customer-facing prioritizing our commercial we meet While enrollment in and expenses. for activity ancillary and trials, that to other readout continuing

in many areas have we grow while We revenue delayed time line. reduced to spend product allow or our

cash ended Regarding our cash second position, cash as described in the December press release million quarter million this morning, and the XXXX. $XXX.X compared we $XXX XX, of of equivalents to with as

to of which into cash to We an includes facility This at of $XX Hercules, and sufficient capital with our on our us debt additional expenditures fund available draw expect runway our projection be this million is to XXXX. currently discretion. a future operations

of their million As Jack third a recent a milestone we of as approval result the $XX payment Simcere from in COSELA receive quarter will mentioned, in China.

China. receive on sales royalties annual expect in to of We COSELA net also double-digit

this to earn internal call year Although these that, back our royalties that royalties Jack closing for purposes, turn assumptions in comments. With I'll our some Jack? modeling XXXX. begin the for are we will may some over

John Bailey

you, and living cancer Will. as your Thank I thank Andrew Jen, always, want Raj, inspiration. And for people to with

day. You goals drive each and toward every our us

you've the heard just today. before me move Now to we that some of recap points let Q&A,

This by growth The quarter during GX full nearly period. own We highest since following initial growth second deployment volume period quarter the was our of OSAMs quarter-over-quarter. the promoted was ended in which quarterly XX% with our was our launch solely COSELA first bile mid-February. their rate team

has payer rejections have few strong, reimbursement had very remained and Third-party date. we to payer

Phase MOA bladder cancer enrollment and starting breast more in X the our enrollment trial and X our action we provide and and our studies. data expect cancer and enrollment from II II III completed triple-negative Phase as of later next with from data described, year, study. And our colorectal CRC recently registrational combination CRC study, completed finally, target results the our in quarter year, in in we quarter, in mechanism XXXX the the the initial of the trials II Phase During trial study Pivotal cancer in bladder Raj trials to ADC hit this first our Phase ongoing

COSELA performance formal to regarding as intend Now as on so. we as previously our enough and communicated, impact we sales provide have GX soon we guidance, data guidance have of do to team

given before we a However, in do tempering the these market of so. understanding month-over-month sales of need dynamics July, we better can

remain of $XX comfortable consensus data-rich the a belts of strong not cancers. Thank As a are excited our under period today, more to this about we sales the under you and be could end with XXXX your quarter XXXX, just morning. analyst for such, for With various and in sitting living lives of the impact of where trilaciclib of us, COSELA currently with million. patients as heading for ahead many time I we through sales net potential

will We XXXX third in on in quarter call. November this again speak format the

virtual next However, our September R&D you on Day us hear will upcoming from at XX.

expectations of a readouts program readouts of We mechanism on the robust to from of preclinical from our expect drugs, variety clinical discuss of potential our discussion updates trilaciclib our including ahead other potential all with anticancer the key the synergies data on trilaciclib, a and work future clinical and action, assessing trials. topics, more the

out and eye will I So invitations over Q&A. close please and to keep for it over the instructions call the coming an turn dial-in that, weeks. With

Operator

of Needham Gil Blum Your first & of question line comes from Company. the

Gil Blum

the on progress. Congrats

it those Is most commercial facilities. just view of future curious most facilities? a what improving company's potential important important. the to I'm the XXX discussed on driving more factor signs Whichever top few items penetration of Is is adding in in think as you growth. kind it on the side we is the improvement. So that show

Andrew Perry

Yes. to happy Gil, take Yes. that.

happy the from. obviously course, portion and of but top all of right we product, those have they reorder lot And XXX in might actually at the in of be runway of an there's their us often seen really a nailed overall use or but product these we're Clearly, their And we've potential just use about. even which QX XX% pathways that of seen some to Those doing with organizations, it, the XX the have a in organizations, to how now. the has a on the all think look then we've a communicating of ton locations. ordered penetration to increased of uptake. Very I see product XX of seen of the right success across a got where now. we're period order they that's product the of there. the organizations you a now through middle organizations there is placement of significant types all in take amazing those that the not process. from actually that it of the We've already rate depth initially period there's some results, that within process in And satellite systems. But optimizing organizations

team really so focused where in that's is on And our QX. QX and

Gil Blum

And forward? should just operation have of kind considering R&D expect flat? that expenses studies remaining Or moving enrollment, a their slowing several we your clinical of completed in

Jennifer Moses

The and continue so flat. them I where have out the studies, we I to data second forward. are would expect they enrolled, We'll that to remain going but would were a be around estimate will to number have close things just of quarter processing. it studies for

Operator

question comes of Pohlman the BTIG. from next of line Your Kaveri

Kaveri Pohlman

in Phase has So treatment first-line the in for the impacted landscape enrollment III TNBC trial? change TNBC,

John Bailey

got KEYTRUDA's solely at That's these it is of question, ADC of more get be outside TNBC. changed of to Jack. of end in so would line in time study. the and I taking it's where since or the eligible enrollment U.S.-based bit wait watch for on to sites patients It XXXX, Phase Thanks sites combination approval U.S. the a This Kaveri. global is our has the enormous The the only for longer was, they XXXX an -- time study study a Yes. guess a a and study U.S. impacting number we've the terms first-line III not

the Phase on first-line III. no So

Kaveri Pohlman

it. Got That's helpful.

first-line in For on expect Trodelvy, previously neoadjuvant and the In efficacy of do this patients progress use TNBC you impact who KEYTRUDA immunotherapy. in trilaciclib the setting in setting? adjuvant the to received

Rajesh Malik

on We potential not. received one. trilaciclib that there that I cycle, on can take immune that immunity its we of action who think of aspects patients that a checkpoint various work is even cancer Based previously the inhibitor. mechanism do in and we impact could an have of

Operator

is from Butler ROTH Next Capital. question of Tony

Charles Butler

you Andrew, about you statement could the X, those could sales I patients additional positive exactly didn't enrolling year? comment you X of some because initiatives a desired most you data then about while have initiatives seen and there be. wondered a some is positive then next be. initiatives, PD-LX And net I those about in quite a into statement even if not new patients, could, and made PD-LX on equivalent made are sales get make both it's about if futility questions. July that that Raj, number negative a PRESERVE what negative might sales you would positive this cohorts, XXX play and you're though versus the what from

And continuing. say about in QX, then what the trials example, you can myelopreservation, given make about when you'll exactly CRC myelopreservation mentioned comments in finally, you for

Andrew Perry

and Thanks oncology, health vary months the mention little well a to of care one. flow I will perhaps a various bit, it Tony. I as some affected patients are trends staff obviously, take couple in does in that the underway. patient summer in and reasons. been flow have the availability Yes, appear by can for initiatives first did

which often, we quite we often lack not earlier actually the confidence earlier. It's product. much some a creating flag is that's us to process issue warning early because And We're just when around excitement focusing or regional because of highlight an the first intercept utilization national, in also can territory on the if it at developing level system, of which that, of and drop just a high-growth there. due accountability they will progress to opportunity those so and accounts accounts

a We're shifted keep some in to out accounts, all our front the our need focus some of and We they have new to patient messages where digital see QX advertising well more as appropriately. materials to of we on resources marketing coming we effectively on product information and also key board come the following make mind. providers use the through sure about how to

So to execution commercial we've of taken the opportunity sharpen number our model. of elements across a

Rajesh Malik

So the enrolling PRESERVE negative. positive right, comers of X, initially, for first we're you're all and PD-LX

data, have you approximately at If positive look PD-LX XX% of the patients tumors.

We are stratifying by PD-LX status.

So we anticipate in tumor that is represented trial. the the PD-LX approximate distribution population in of be will this what

stratifying, that hazard in to appropriate the PD-LX in So we're think to you XX%. even than was negative, XX% the the because in the way less X.X%. if And we evaluate And still it's ratio both. recall, effect

definitely there meaningful effect So was there. a

that and the will key duration patient-reported and of PRESERVE second we'll then severe be be X, And analyzing outcomes. the to data, severe primary so neutropenia reporting data neutropenia, and

blinded will continue be trial so event-driven any outcomes, will the We to

OS will and trial those the for readouts. PFS so outcomes, event-driven continue Gap] to [Audio

as will well the able rate the we data. So be response data to as report myeloprotection

Operator

Your of H.C. next question White is Wainwright. from Ed

Edward White

I curious any of you if was just COSELA? use off-label data potential on have

Andrew Perry

significant We has quite through claims lag that it because get to has a on come sources. information it

the I use. percentages information of that estimate would of I single-digit pertains lot But second quarter. have So a a to don't off-label

Edward White

importance now forward? majority that. of live Maybe expect -- calls. just see earlier then, to that do And of you a continue sales versus us you review mentioned And had virtual of Andrew, the going you this with majority the you could

Andrew Perry

whole prescriber, salesperson forward whoever on channels And with continue the little and old they've staff, the staff, anticipate on our of they big [ advantage, ] is goes our getting calling prescriber the a I they're pharmacy, We're and of to up having what vastly reimbursement. going to very call. nursing office oncology mind them a this, one-dimensional actually. kind they're will the the any is it an sell that activities specialty account, I of for just total view in product, who product. idea The office, can a an on front-office across calling no the only maybe is accelerate picture adoption of into into product school but and and of calling there's product, which not a when that my to competent engaged they're it takes do on and getting calling an and substitute capable built oncology and mind build never think,

Edward White

is on headwinds And for going solutions Wondering of you you sales to seeing the launch. during positives that just a that lot perhaps my headwinds? have you mentioned what and you're last those question potential what

Andrew Perry

I much. don't think they've really changed too

we because us the can more with actually we've been think, I better together identifying health provider. a see willingness about any that showed real-world we the of into awareness conversation had the the And really patient. to profound, and burden into promotion we're product to think care myelosuppression, than the it's thought, how I converting a much prescribe really where starting recently to pleased NCCN, do of is and at maybe how it evaluate that some of creates data can get which presented

of of which is component, process an care. it which the is COSELA problem efficiency proactively next many dealing really And And the part of or these are getting then an benefits quality waiting a deeply a for of networks there's with care of now happen the for multi-lineage on system. offer. embedded only myeloprotection finally, habit kind providers for And IT rely institutions, then of and EMR that organizations, with system XX that just versus to shifting and can years of

you bit the for those P&T make takes you physician even when you formulary systems, scenes. when to so sure optimal COSELA enthusiastic behind placement have need navigation that in still and you're of the And have review, even review, have systems, out you working those in support, even a when little

Operator

next Your is Wedbush from of David Securities. question Nierengarten

David Nierengarten

on side. Congrats clinical clinical it's progress the impressive. couple here, the on the of questions side, on especially A

read background I Or And is, ADC bladder metal those come another way to get it combination neutropenia in trilaciclib question on what the and those will effects how is out? study For about with to should treated background could currently on significant that? are straight there is ask or know of be cancer expect it the And know, and trying we PFS, but for to primary study, maybe for going out thinking there. preservation patients? is kind there? like in a there a endpoint or things that other to a we of agents anything is the rates rates nuances myelopreservation the Just the Neulasta myelosuppression generally feel settings,

Rajesh Malik

Yes.

Starting myelosuppression, quite with be neutropenia. the of rates will we of significant outcomes So neutropenia, thrombocytopenia. have anemia, actually that does so looking at Trodelvy it

there potential we there's improvement, which So to show combination. feel better translate to the tolerability of an could opportunity

reported things actually the AUC was this year did looking at with that exposure they Pop this of of Trodelvy a model. associated greater One a at response efficacy PK ASCO an that analysis was and

dose And Trodelvy. could so be important for maintaining intensity

that that something So that be we'll in looking is at study.

the includes to XX bladder, study. say, the the occur so well. gem-platinum, it's is be combinations this schedule, as day does On we'll And I TNBC same cis at. carbo, regimen both our going chemo as to be Myelosuppression readouts regimen, given a those and and that know, it's you is similar should looking which with

David Nierengarten

benefit. but endpoint, Just statistically for a double able be it's secondary a to to track you'll check,

Rajesh Malik

Yes.

objective is David, to secondary alpha Sorry, a and no there's just sign. clarify, it

additional So data be but regimens. important be it descriptive, we evaluate myeloprotection different will it will across as

Operator

Instructions] [Operator Anupam JPMorgan. of Your from Rama question next is

Anupam Rama

have your action scenario the opinion? X what's PRESERVE the the Just say, And how mechanism of a of in this cited on that studies of Kind view might there study. on call. change efficacy the some the versus of, been that trilaciclib MOA question win study,

Rajesh Malik

in trilaciclib well analysis What as the impact Anupam, the blood shown we've clinical cell T is previously is our of largely. Raj compartment that in preclinical from as studies here. studies peripheral with

regulatory be numbers the just of we'll at T T but which immunohistochemistry, looking CDX-positive also more not subsets effect So sort cells, readouts, cells, on functional by cells present. but other are activated,

increase transient One T I past inhibition think of that is memory can in cells. we've the formation the things interesting the discussed CDX-positive CDKX/X of that

looking be we'll could So at something as that that interested well. in be

happening rather what's peripheral this make going tumor because so easier within can also tumor it's it's much to blood. We're look blood with very blood assessment peripheral of course, microenvironment. forward the to with immune going going we the at in So the look holistic be looking mechanism. would, from these going at a of to help And patients peripheral us the than forward correlations

would can your terminology microenvironment be the trilaciclib variety in of ways. a showing modulate win that if immune scenario a So tumor in really

Operator

question is Your next of from Cowen. Troy Langford

Troy Langford

the on Congrats quarter. great in progress the

Just X launch us. the on quick ones from COSELA

do new How do it initiatives. long sales sales? effect think on of before out will effect a time? see And or X, you think an period that. take we a think an quarterly over after you'll longer So follow-up the see it I could on will over have play you do you quarter First, a then

Andrew Perry

necessarily to account predictions at What we level, would too improvements. we're rapid in to many I account provide by the a think can see there. position not due execution is say I improvement

So we'll be looking for account. that by account

up As second it quarter-to-quarter, at point. to guess I ladders don't want to how that this

Troy Langford

last yet? handful the you represent more in does something reached into anything that or that question then have COSELA these distinguish And like break next that? to accounts else difficult is bigger of are systems top particular Do all haven't the just, I

Andrew Perry

Yes. It a can be variety.

of job So get like some really them. And to organizations front launch and COSELA on don't completely at the sometimes our retread. our some they are or there would commercial, of them very the In the looked out ones, recent reevaluate take shots information didn't are mixture is information those very, be cases. in these organizations product organizations, in to they longer cases, goal. all community course, just and always many fewer they there's a the period, to can of early many, it's seal we that that more because have And and they of And access knew accounts maybe academic needed. in get to no

So once they've go to back. they the like don't made decision,

that time. have looking yet place some in COSELA, So those not health for a experience both have environment. the little as more success across at the they're organizations with with organizations for with to us. they their be course, actually to care I'm going excited see COSELA those We're getting bit to XXX in and got adopted community we decisions that will that docket happy those bear take can discussions we've top And sure it. hope across on continue of plans of are And peers and academic more

Operator

conference Bailey for remarks. I Mr. now like to closing Jack the back to would turn

John Bailey

Thank you we certainly you us Thank we keeping hope you. operator. Great. updated And today to progress. forward you, joining well. Thank you look and as for all stay

Operator

That conference concludes today's for call. Thank you all participating.

disconnect. You may now

G1 Therapeutics (GTHX) 3 Aug 222022 Q2 Earnings call transcript